Literature DB >> 11738538

Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia.

Daniel Schuepbach1, Matcheri S Keshavan, Julie A Kmiec, John A Sweeney.   

Abstract

Patients with first-episode schizophrenia show significant cognitive impairments even at this early phase of their illness. Antipsychotic medication improves clinical symptomatology, but the effectiveness of this treatment on neuropsychological deficits remains unclear. We investigated clinical symptom and neuropsychological performance change in 34 unmedicated first-episode psychotic patients (17 males, 17 females) from the time prior to treatment until 33.6+/-11.3 days after treatment initiation at which time patients demonstrated meaningful recovery from psychosis. Twenty-four matched healthy subjects were also studied. Performance in most neuropsychological functions (language skills, attention, nonverbal learning and reasoning, motor speed) remained stable for the group as a whole. However, reduction in negative symptoms was significantly correlated with performance increases in verbal fluency and attention. Higher negative symptom recovery was associated with improvement of cognitive performance to levels approaching those of healthy subjects, whereas low or no negative symptom improvement was associated with stable or decreased cognitive performance. Reduction in positive symptoms was not associated with change in cognitive abilities. These findings suggest a linkage between early, treatment-induced improvements in negative symptoms and reductions in distinct cognitive deficits.

Entities:  

Mesh:

Year:  2002        PMID: 11738538     DOI: 10.1016/s0920-9964(01)00195-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

1.  Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study.

Authors:  Margot Albus; Werner Hubmann; Fritz Mohr; Susanne Hecht; Petra Hinterberger-Weber; Nichi-Niels Seitz; Helmut Küchenhoff
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-10-09       Impact factor: 5.270

Review 2.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

3.  A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia.

Authors:  Mario Fioravanti; Olimpia Carlone; Barbara Vitale; Maria Elena Cinti; Linda Clare
Journal:  Neuropsychol Rev       Date:  2005-06       Impact factor: 7.444

Review 4.  Cognitive control deficits in schizophrenia: mechanisms and meaning.

Authors:  Tyler A Lesh; Tara A Niendam; Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

Review 5.  Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond.

Authors:  Emre Bora; Murat Yücel; Christos Pantelis
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

6.  Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.

Authors:  Rosa Ayesa-Arriola; Jose Manuel Rodríguez-Sánchez; Rocío Pérez-Iglesias; Roberto Roiz-Santiáñez; Obdulia Martínez-García; Jose Sánchez-Moreno; Rafael Tabarés-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

7.  Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.

Authors:  Joseph Ventura; Gerhard S Hellemann; April D Thames; Vanessa Koellner; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-22       Impact factor: 4.939

8.  The course of neurocognition and social functioning in individuals at ultra high risk for psychosis.

Authors:  Tara A Niendam; Carrie E Bearden; Jamie Zinberg; Jennifer K Johnson; Mary O'Brien; Tyrone D Cannon
Journal:  Schizophr Bull       Date:  2007-04-09       Impact factor: 9.306

9.  Addition of home-based cognitive retraining to treatment as usual in first episode schizophrenia patients: a randomized controlled study.

Authors:  Shantala Hegde; Shobini L Rao; Ahalya Raguram; Bangalore N Gangadhar
Journal:  Indian J Psychiatry       Date:  2012-01       Impact factor: 1.759

10.  Initial Results of Tests Using GSR Biofeedback as a New Neurorehabilitation Technology Complementing Pharmacological Treatment of Patients with Schizophrenia.

Authors:  Renata Markiewicz; Beata Dobrowolska
Journal:  Biomed Res Int       Date:  2021-06-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.